Life Sciences

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development […]

The installation and validation of our LabVantage Laboratory Information Management System (LIMS) is complete in our Philadelphia site!   Staff at our Philadelphia site worked together with cross-functional teams in Quality, Operations, IT, CSols, Inc. and LabVantage (vendor) to complete the installation and validation of a highly-functional and GMP compliant LIMS system. Lou Forcellini, site

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Drug Development and Delivery recently interviewed our very own, Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace Analytical® Life Sciences (PLS). After two recent acquisitions, Pace now operates five state-of-the-art facilities, and is well-equipped to handle almost any project regardless of scope or

Summary: In an effort to improve stability and shelf life of a drug, the active ingredients in many therapeutics are typically mixed with a number of other inactive chemicals. The end result of this process, called formulation, is commonly a liquid solution or suspension. However, for certain drugs, which are prone to degradation or aggregation,

Thursday, October 15, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST Event Overview: Determining the polymorphism of a drug—the propensity of a molecule to crystallize in different crystalline arrangements, to form crystalline salts and/or non-salt cocrystals—allows for rational selection of the proper solid form/polymorph for further development. In this webcast, learn about the

ON DEMAND WEBINAR: Pharmaceutical Development of Oligonucleotides Oligonucleotides are an emerging class of DNA and RNA therapeutics that address a number of unmet medical needs. As with many biopharmaceuticals, the complex structure of oligonucleotides makes their large-scale synthesis both challenging and imperfect. A number of impurities are generated during manufacturing, many of which are hard